Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Antiviral Screening in Patients With Early Symptomatic Dengue
NCT06551844Phase 2
Key facts
- Status
- Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Countries
- 2
- Sponsor
- Oxford University Clinical Research Unit
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, RNA-Targeting Small Molecules
- Conditions
- dengue fever
01
Overview
Phase 2, randomised, open-label trial of molnupiravir, VIS513 and remdesivir in dengue fever (4 arms), sponsored by Oxford University Clinical Research Unit. Primary endpoints: Viral clearance rate at 5 days and Number of Adverse Events (grade 3, 4 and 5) at 30 days. Started Apr 2026; status: recruiting.
02
Design
4 arms- Study design
- RandomizedOpen-label
Standard of care
Standard of care (no study drug)
Molnupiravir
800mg po bid for 5 days
VIS513
Single dose of 6mg/Kg IV over 2 hours
Remdesivir
200mg loading dose on day 1, followed by 100mg once daily from day 2 to day 5 (adults/children >= 40Kg)
03
Who it enrols
Patients aged 10 or older with early symptomatic dengue (fever < 48 hours, positive NS1 test), excluding those with severe dengue, pregnancy, or eGFR < 30.
04
Endpoints
Primary
Viral clearance rate
Number of Adverse Events (grade 3, 4 and 5)
Secondary
Area under the viremia curve
Viral log reduction
NS1 clearance time
Number of patients progress to severe dengue (WHO 2009 criteria)
Number of patients requiring for ICU admission
Fever clearance time
Platelet nadir
Maximum AST/ALT
Beyond the preview
Go deeper on NCT06551844.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551844.